Welcome!

News Feed Item

Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Baxter International Inc. Analyst Notes 

On April 2, 2014, Baxter International Inc. (Baxter) announced that it has agreed to acquire all of Chatham Therapeutics, LLC's (Chatham) outstanding membership interests. The Company stated that it will acquire Chatham's developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. Baxter informed that under the terms of agreement, the Company will make an initial payment of $70 million to acquire all of the outstanding membership interests of Chatham and may make additional payments in the future based on specified development, regulatory and commercial milestones. In another announcement dated, April 3, 2014, the Company stated that it will host a quarterly conference call to discuss its Q1 2014 financial results on April 17, 2014 at 7:30 a.m. CT. Baxter stated that the call will be webcast and can be accessed at the Company website. The full analyst notes on Baxter International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/BAX/report.pdf

--

AcelRx Pharmaceuticals, Inc. Analyst Notes 

On March 25, 2014, AcelRx Pharmaceuticals, Inc. (AcelRx) announced the appointment of Timothy E. Morris as the Company's CFO. AcelRx informed that Mr. Morris will be responsible for managing the Company's finance operations, information systems and human resource and investor relations functions as part of his new role. The Company stated that he succeeds Jim Welch, who had served as CFO since October 2010. According to the AcelRx, Morris holds 30 years of professional finance and accounting experience out of which 18 years of experience as CFO and prior to joining AcelRx he served as CFO at VIVUS Inc. Commenting on the appointment, Richard King, President and CEO of AcelRx, stated, "Tim's recent knowledge in transitioning a development-stage company to commercial capability in terms of finance, accounting, information systems and personnel, coupled with his experience in structuring and valuing transactions, strategic planning and executive management, make him an invaluable addition to our company." The full analyst notes on AcelRx Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/ACRX/report.pdf

--

Synta Pharmaceuticals Corp. Analyst Notes 

On April 9, 2014, Synta Pharmaceuticals Corp.'s (Synta Pharmaceuticals) stock increased 10.07%, to close at $4.48. For the past five-day trading period, the Company's shares gained 11.16% compared to the Nasdaq Composite which rose 0.98% during the same period. The full analyst notes on Synta Pharmaceuticals Corp. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/SNTA/report.pdf

--

The Spectranetics Corporation Analyst Notes 

On March 27, 2014, The Spectranetics Corporation (Spectranetics) announced early success of the EXCITE ISR clinical trial, achieving highly significant statistical superiority in both safety and efficacy. According to the Company, the outcome was achieved without any borrowing from the PATENT registry. The Company informed that based on this result, Spectranetics has concluded enrollment in the EXCITE ISR trial and will submit the 510(k) application to the Food and Drug Administration (FDA) on the announcement date. Spectranetics President and CEO, Scott Drake, commented, "We are in the process of developing a new, necessary standard of care for ISR patients. Safety and efficacy superiority are the bedrock of our strategy to unlock this $750 million target market. Early success with EXCITE is another critical step toward our goal of accelerating top line growth, expanding gross margins and achieving meaningful operating leverage." Spectranetics added that In-stent restenosis (ISR) occurs when a previously placed stent becomes occluded, or blocked, and is considered to be a challenging condition to treat. The full analyst notes on The Spectranetics Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04112014/SPNC/report.pdf

--

NuVasive, Inc. Analyst Notes 

On April 9, 2014, NuVasive, Inc.'s (NuVasive) stock gained 0.40%, closing at $35.46. Over the past six months of trading, NuVasive's shares advanced 43.15% compared to the Nasdaq Composite which went up by 13.75% during the same trading period. The full analyst notes on NuVasive, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/NUVA/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Open Source Software development, collaboration, discovery and download on the web serving over 32 million viewers, 150 million downloads and over 460,000 active development projects each and every month.
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that SIGMA Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. uLaser flow inspection device from the Japanese top share to Global Standard! Then, make the best use of data to flip to next page. For more information, visit http://www.sigma-k.co.jp/en/.
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
The last two years has seen discussions about cloud computing evolve from the public / private / hybrid split to the reality that most enterprises will be creating a complex, multi-cloud strategy. Companies are wary of committing all of their resources to a single cloud, and instead are choosing to spread the risk – and the benefits – of cloud computing across multiple providers and internal infrastructures, as they follow their business needs. Will this approach be successful? How large is the ...
Your clients expect transactions to never fail, cloud access to be fast and always on, and their data to be protected - no exceptions. Hear about how Secure Service Container (SSC), an IBM-exclusive open technology, enables secure building and hosting of next-generation applications, both cloud and on-premises. SSC protects the full stack from external and insider threats, allows automatic encryption of data in-flight and at-rest, and is tamper-resistant during installation and runtime – with no...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp em...
SYS-CON Events announced today that Interface Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Interface Corporation is a company developing, manufacturing and marketing high quality and wide variety of industrial computers and interface modules such as PCIs and PCI express. For more information, visit http://www.i...